Damora Therapeutics is a clinical-stage biotechnology company developing targeted biologics for blood disorders driven by mutant calreticulin (mutCALR) myeloproliferative neoplasms such as essential thrombocythemia and myelofibrosis. Its pipeline centres on monoclonal antibody approaches designed as disease-modifying treatments with subcutaneous delivery for convenience. With little or no commercial revenue yet, the company serves a specialised hematology niche rather than broad oncology markets.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 0 | — | -3.4 | — |
| Q3 2025 | 0 | — | -3.1 | — |
| Q4 2025 | 0 | — | -200.7 | — |
| Q1 2026 | 0 | — | -27.8 | — |
| Q2 2026 | 0 | — | -31.2 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: TMC the metals company Inc. (TMC), Univest Financial Corporation (UVSP), Alpha Tau Medical Ltd. (DRTS), Winmark Corporation (WINA), Tandem Diabetes Care, Inc. (TNDM), Fluence Energy, Inc. (FLNC)